Imugene (ASX:IMU) share price lifts on major collaboration announcement

The clinical trial will evaluate the safety and efficacy of a combination drug treatment approach in cancer patients.

| More on:
Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Imugene share price rises on collaboration announcement 
  • Merk & Co. has a market cap of US$198 billion 
  • The trial is intended to improve the outcomes for cancer patients 

The Imugene Limited (ASX: IMU) share price is marching higher in early trade. Imugene shares are up 4% even as the All Ordinaries Index (ASX: XAO) tumbles 1%.

The Imugene share price closed yesterday at 25 cents and is currently trading at 26 cents.

Below we look at the immuno-oncology company's clinical trial collaboration announcement.

What collaboration was announced?

The Imugene share price is gaining after the company reported that it's entered into a new clinical trial collaboration and supply agreement with US pharmaceutical giant Merck & Co. Inc. (NYSE: MRK), under its tradename MSD.

The collaborative trial will treat patients with HER-2 positive gastric cancer with Imugene's HER-Vaxx, combined with MSD's pembrolizumab. The trial will evaluate both the safety and efficacy of the combined treatment approach.

Commenting on the collaboration, Leslie Chong, Imugene's CEO, said:

HER-Vaxx has already shown a tolerable safety profile and encouraging efficacy in patients with metastatic HER-2 positive gastric cancer, and we look forward to further evaluating HER-Vaxx with pembrolizumab in a relapsed/refractory metastatic setting.

This collaboration with MSD is significant for our company as it provides the opportunity to optimize and enhance our formulations and utility in an additional setting in an effort to improve outcomes for more patients.

Imugene said the main goal of the study is to evaluate the safety and response rate of the combination therapy. It will also assess patients' "duration of response, progression free survival, overall survival, and biomarker evaluation".

In accordance with the agreement, Imugene will sponsor and fund the clinical study. It said this will be done from its existing budgets and resources.

In return, MSD will provide pembrolizumab for the duration of the study, which is expected to run for at least 24 months.

Imugene share price snapshot

The Imugene share price has been a stellar performer over the past 12 months, up 112%. By comparison, the All Ordinaries has gained 5% over that same time.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »